Keryx Biopharmaceuticals Inc. Reaches New 12-Month High at $16.18 (KERX)
Keryx Biopharmaceuticals (NASDAQ:KERX)’s share price reached a new 52-week high on Friday, American Banking & Market News reports. The company traded as high as $16.18 and last traded at $15.45, with a volume of 8,335,572 shares traded. The stock had previously closed at $14.24.
A number of analysts have recently weighed in on KERX shares. Analysts at JPMorgan Chase & Co. reiterated a “positive” rating on shares of Keryx Biopharmaceuticals in a research note to investors on Thursday, November 7th. Separately, analysts at Brean Capital reiterated a “buy” rating on shares of Keryx Biopharmaceuticals in a research note to investors on Tuesday, November 5th. Finally, analysts at JMP Securities reiterated an “outperform” rating on shares of Keryx Biopharmaceuticals in a research note to investors on Monday, November 4th. They now have a $22.00 price target on the stock, up previously from $14.00. Eight research analysts have rated the stock with a buy rating, Keryx Biopharmaceuticals currently has an average rating of “Buy” and an average target price of $16.71.
In other Keryx Biopharmaceuticals news, CEO Ron Bentsur sold 5,257 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.57, for a total value of $66,080.49. Following the sale, the chief executive officer now directly owns 880,419 shares of the company’s stock, valued at approximately $11,066,867. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.19) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.08. During the same quarter last year, the company posted ($0.08) earnings per share.
Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.